# Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC

> **NCT02947113** · PHASE2 · WITHDRAWN · sponsor: **The Netherlands Cancer Institute**

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **RADIATION:** hypofractionated radiotherapy
- **DRUG:** Pemetrexed
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT02947113
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** New studies available with immunotherapy so recruitment is no longer acceptable.
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947113, "Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02947113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*